10-Q · May 14, 2026
NextPlat Corp's Q4 2026 results revealed revenue of $12.8 million, a decrease from $13 million in Q4 2025, continuing the trend of falling revenues over recent quarters. The gross margin improved marginally to 14.3%,…
Earnings analysis · 10-Q
NXPL earnings analysis
Filed August 13, 2026 · Our reading of the company's report
The latest report
NextPlat delivered $11.881 million of revenue and $(0.05) diluted EPS, exceeding consensus estimates of $11.0 million and $(0.21), respectively. Gross margin improved to approximately 40.0%, while six-month operating…
Read full summary
NextPlat delivered $11.881 million of revenue and $(0.05) diluted EPS, exceeding consensus estimates of $11.0 million and $(0.21), respectively. Gross margin improved to approximately 40.0%, while six-month operating cash outflow improved to $1.498 million from $3.100 million in the prior-year period. However, cash was $11.940 million, two material weaknesses remained unremediated as of June 30, 2026, and the company carried a $1.75 million litigation accrual. Management expects positive operating income for the remainder of 2026, but liquidity, healthcare collections, litigation, and control remediation remain important risks.
Reported figures
- Earnings per share
- $-0.05
- Gross margin
- 40.0%
What stood out
-
Revenue and EPS beat estimates
Revenue was $11.881 million, up approximately 21% sequentially from $10 million in 2026 Q1 and above the $11.0 million consensus estimate. Diluted EPS was $(0.05), versus $(0.42) in 2026 Q1 and the $(0.21) estimate.
-
Gross margin reached approximately 40%
Gross margin improved to approximately 40.0% from 34.6% in 2026 Q1, an increase of approximately 5.4 percentage points, supported by a more favorable healthcare mix.
-
Operating cash burn improved
Net cash used in operating activities was $1.498 million for the six months ended June 30, 2026, compared with $3.100 million in the prior-year period, an improvement of approximately $1.6 million.
-
Cash remains available with no capex
Cash at June 30, 2026 was $11.940 million, compared with $16.635 million at June 30, 2025. No investing cash flows were recorded during the first six months of 2026.
-
Cost controls supported cash flow
Cash paid for inventory purchases and other costs of revenue decreased by approximately $5.4 million year over year, while cash paid for salaries and related expenses decreased by approximately $1.2 million.
What to watch
-
Ongoing cash burn and liquidity risk
The company reported $1.498 million of operating cash outflow for the first six months of 2026, while cash declined to $11.940 million from $16.635 million a year earlier. Continued losses could pressure liquidity despite the absence of investing cash outflows.
-
Material weaknesses remain unresolved
Disclosure controls were not effective as of June 30, 2026, and two material weaknesses—relating to the PBM performance bonus receivable and PIPE warrant modification accounting—remained unremediated. Management expects to conclude remediation of the PBM weakness by December 31, 2026, subject to continued effective operation and testing.
-
$1.75 million litigation exposure
The company maintained an approximately $1.75 million accrual as of June 30, 2026 for the former RXMD stockholder litigation. Management stated that the ultimate loss could differ materially from the accrued amount.
-
Healthcare collections remain pressured
Healthcare operating cash receipts decreased by approximately $5.6 million year over year due to lower revenue and the timing of receivable collections, indicating continued collection and reimbursement sensitivity in the healthcare business.
-
Debt repayments consume cash
Net cash used in financing activities was approximately $0.288 million for the six months ended June 30, 2026, attributable to repayment of notes payable, limiting financing cash available to offset operating losses.
Management's outlook
No quantified revenue or EPS guidance was provided in the filing. Management expects sustainable positive operating income for the remainder of 2026 and positive earnings moving forward; the approximately 20% organic healthcare growth outlook was not quantitatively changed.
Earlier filings 1
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.